Teacher Retirement System of Texas Has $1.08 Million Holdings in Elanco Animal Health Incorporated $ELAN

Teacher Retirement System of Texas increased its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 4.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 75,382 shares of the company’s stock after acquiring an additional 3,110 shares during the quarter. Teacher Retirement System of Texas’ holdings in Elanco Animal Health were worth $1,076,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Allworth Financial LP increased its stake in shares of Elanco Animal Health by 791.7% in the first quarter. Allworth Financial LP now owns 2,354 shares of the company’s stock worth $25,000 after purchasing an additional 2,090 shares during the period. Wealthquest Corp bought a new stake in Elanco Animal Health during the 1st quarter valued at approximately $56,000. Caitong International Asset Management Co. Ltd grew its holdings in Elanco Animal Health by 261.6% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 4,039 shares of the company’s stock valued at $58,000 after buying an additional 2,922 shares during the last quarter. Covestor Ltd increased its position in Elanco Animal Health by 510.9% in the 1st quarter. Covestor Ltd now owns 7,087 shares of the company’s stock worth $74,000 after buying an additional 5,927 shares during the period. Finally, MRP Capital Investments LLC increased its position in Elanco Animal Health by 60.0% in the 1st quarter. MRP Capital Investments LLC now owns 8,000 shares of the company’s stock worth $84,000 after buying an additional 3,000 shares during the period. 97.48% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ELAN has been the subject of several research reports. Stifel Nicolaus increased their price objective on Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Zacks Research raised shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a report on Friday, October 3rd. Wall Street Zen lowered shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. UBS Group upped their price objective on shares of Elanco Animal Health from $25.00 to $27.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Leerink Partners raised Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 target price on the stock in a research report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $20.29.

Elanco Animal Health Price Performance

Shares of Elanco Animal Health stock opened at $21.48 on Friday. The firm has a market cap of $10.67 billion, a P/E ratio of 358.06, a price-to-earnings-growth ratio of 3.30 and a beta of 1.71. The firm’s 50-day simple moving average is $20.11 and its 200-day simple moving average is $16.07. Elanco Animal Health Incorporated has a twelve month low of $8.02 and a twelve month high of $22.98. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.40 and a current ratio of 2.60.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.06. The firm had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.09 billion. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.51%. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.13 earnings per share. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS. As a group, research analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.